MUFG Securities EMEA plc Invests $9.85 Million in Becton, Dickinson and Company (NYSE:BDX)

Key Points

• MUFG Securities EMEA plc has acquired a new stake of 43,000 shares in Becton, Dickinson and Company, valued at approximately $9.85 million, as reported in their first quarter SEC filing.
• Insider trading activity includes sales by executives, with EVP David Shan selling 1,166 shares and reducing his stake by 20.31%, and Michael David Garrison selling 1,185 shares, reducing his position by 19.52%.
• Becton, Dickinson and Company recently announced a quarterly dividend of $1.04 per share, reflecting an annualized yield of 2.1% with a payout ratio of 79.39%.

MUFG Securities EMEA plc purchased a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 43,000 shares of the medical instruments supplier's stock, valued at approximately $9,850,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $27,000. REAP Financial Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 55 shares during the period. Alpine Bank Wealth Management bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 99 shares during the period. Finally, Nexus Investment Management ULC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $34,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded down $0.97 on Monday, reaching $192.53. The stock had a trading volume of 2,770,580 shares, compared to its average volume of 3,342,677. The business's 50-day moving average price is $175.81 and its 200 day moving average price is $198.42. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The stock has a market cap of $55.19 billion, a P/E ratio of 34.63, a price-to-earnings-growth ratio of 1.46 and a beta of 0.20. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter last year, the company earned $3.50 earnings per share. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a research report on Thursday, May 1st. Barclays dropped their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Piper Sandler reiterated a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday. Finally, Stifel Nicolaus lowered their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $211.44.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Shan sold 1,166 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,214 shares of company stock valued at $579,206 in the last quarter. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.